Literature DB >> 16214600

Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study.

Sheila K West1, Beatriz Munoz, Harran Mkocha, Martin J Holland, Aura Aguirre, Anthony W Solomon, Allen Foster, Robin L Bailey, David C W Mabey.   

Abstract

BACKGROUND: Data from studies done in communities where trachoma is mesoendemic suggest that ocular infection with Chlamydia trachomatis can be eliminated after one mass treatment with antibiotics. However, there are no comparable long-term data from trachoma hyperendemic communities. Our aim, therefore, was two-fold: first, to ascertain the disease pattern of trachoma and ocular infection with C trachomatis in a trachoma hyperendemic community after mass treatment; and, second, to ascertain the risk factors for incident infection.
METHODS: We did a longitudinal study of a trachoma hyperendemic community (n=1017) in Tanzania. We did surveys, including ocular swabs, at baseline, 2, 6, 12, and 18 months to identify the presence, and quantity, of C trachomatis after single mass treatment of all individuals aged 6 months or older with azithromycin 20 mg per kg; pregnant women without clinical disease received topical tetracycline.
FINDINGS: Mass treatment (coverage 86%) significantly reduced the prevalence of infection from 57% (495 of 871) to 12% (85 of 705) at 2 months. Infection remained fairly constant to 12 months, with evidence of increasing numbers and load of infection by 18 months post-treatment. Incident infection at 6 months was 3.5-times more likely if another member of the household had more than 19 organisms per swab at 2 months. Travel outside the village, and visitors to the household, did not increase the risk of infection within households up to 12 months.
INTERPRETATION: In this trachoma hyperendemic community, infection levels after high antibiotic coverage persisted at a low level to 18 months, with evidence for re-emergence after 1 year. Fairly light loads of infection were associated with household transmission. Yearly mass treatment over a few years could be sufficient to eliminate infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16214600     DOI: 10.1016/S0140-6736(05)67529-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  52 in total

1.  Elimination of trachoma: are we in danger of being blinded by the randomised controlled trial?

Authors:  H R Wright; J E Keeffe; H R Taylor
Journal:  Br J Ophthalmol       Date:  2006-11       Impact factor: 4.638

2.  Trachoma, antibiotics and randomised controlled trials.

Authors:  B Shapiro; K Dickersin; T Lietman
Journal:  Br J Ophthalmol       Date:  2006-12       Impact factor: 4.638

3.  Trachoma: ancient scourge, disease elimination, and future research.

Authors:  Charles Knirsch
Journal:  Curr Infect Dis Rep       Date:  2007-01       Impact factor: 3.725

4.  Topical azithromycin: new evidence?

Authors:  Hannah Kuper; Richard Wormald
Journal:  Br J Ophthalmol       Date:  2007-05       Impact factor: 4.638

Review 5.  Chlamydia trachomatis today: treatment, detection, immunogenetics and the need for a greater global understanding of chlamydial disease pathogenesis.

Authors:  D Dean
Journal:  Drugs Today (Barc)       Date:  2009-11       Impact factor: 2.245

6.  Where do we go from here? Prevalence of trachoma three years after stopping mass distribution of antibiotics in the regions of Kayes and Koulikoro, Mali.

Authors:  Sanoussi Bamani; Jonathan D King; Mamadou Dembele; Famolo Coulibaly; Dieudonne Sankara; Yaya Kamissoko; Jim Ting; Lisa A Rotondo; Paul M Emerson
Journal:  PLoS Negl Trop Dis       Date:  2010-07-06

7.  Mass treatment with azithromycin for trachoma control: participation clusters in households.

Authors:  Elizabeth N Ssemanda; Beatriz Munoz; Emma M Harding-Esch; Tansy Edwards; Harran Mkocha; Robin L Bailey; Ansumana Sillah; Dianne Stare; David C W Mabey; Sheila K West
Journal:  PLoS Negl Trop Dis       Date:  2010-10-05

8.  Targeting antibiotics to households for trachoma control.

Authors:  Isobel M Blake; Matthew J Burton; Anthony W Solomon; Sheila K West; María-Gloria Basáñez; Manoj Gambhir; Robin L Bailey; David C W Mabey; Nicholas C Grassly
Journal:  PLoS Negl Trop Dis       Date:  2010-11-02

9.  Importance of coverage and endemicity on the return of infectious trachoma after a single mass antibiotic distribution.

Authors:  Takele Lakew; Wondu Alemayehu; Muluken Melese; Elizabeth Yi; Jenafir I House; Kevin C Hong; Zhaoxia Zhou; Kathryn J Ray; Travis C Porco; Bruce D Gaynor; Thomas M Lietman; Jeremy D Keenan
Journal:  PLoS Negl Trop Dis       Date:  2009-08-25

10.  When can antibiotic treatments for trachoma be discontinued? Graduating communities in three African countries.

Authors:  Kathryn J Ray; Thomas M Lietman; Travis C Porco; Jeremy D Keenan; Robin L Bailey; Anthony W Solomon; Matthew J Burton; Emma Harding-Esch; Martin J Holland; David Mabey
Journal:  PLoS Negl Trop Dis       Date:  2009-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.